Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.

about

Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.Cross-talk between two antioxidants, thioredoxin reductase and heme oxygenase-1, and therapeutic implications for multiple myeloma.

P2860

Q35969785-1C6FA83F-BAAD-499D-B393-131743AB5795 Q41882913-3CA1C678-2A76-4692-9325-449DFD9AB4C6

P2860

Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.

Item

http://www.wikidata.org/entity/Q38989789

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Carfilzomib for the treatment ...... r refractory multiple myeloma.

@en

type

Item

label

Carfilzomib for the treatment ...... r refractory multiple myeloma.

@en

prefLabel

Carfilzomib for the treatment ...... r refractory multiple myeloma.

@en

P1476

Carfilzomib for the treatment ...... r refractory multiple myeloma.

@en

P2093

A Keith Stewart

http://www.w3.org/2001/XMLSchema#string

P2860

From clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myeloma

Crystal structure of the human 20S proteasome in complex with carfilzomib

Clinical use of proteasome inhibitors in the treatment of multiple myeloma

Cathepsin g is required for sustained inflammation and tissue injury after reperfusion of ischemic kidneys

Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.

Carfilzomib: a novel second-generation proteasome inhibitor

A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.

P304

2121-2136

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.15.123

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26125319

http://www.w3.org/2001/XMLSchema#string

Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.

about

P2860

P2860

Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698